AKBA
Akebia TherNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$402.38M
P/E Ratio
—
EPS
$-0.02
Beta
0.35
52W High
$4.08
52W Low
$1.14
50-Day MA
$1.38
200-Day MA
$2.09
Dividend Yield
—
Profit Margin
-2.26%
Forward P/E
34.84
PEG Ratio
0.00
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $236.20M |
| Gross Profit (TTM) | $195.84M |
| EBITDA | $27.27M |
| Operating Margin | -10.50% |
| Return on Equity | -553.00% |
| Return on Assets | 5.44% |
| Revenue/Share (TTM) | $0.92 |
| Book Value | $0.12 |
| Price-to-Book | 11.48 |
| Price-to-Sales (TTM) | 1.70 |
| EV/Revenue | 1.021 |
| EV/EBITDA | 11.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 23.90% |
| Shares Outstanding | $268.25M |
| Float | $262.21M |
| % Insiders | 4.00% |
| % Institutions | 47.40% |
Historical Volatility
HV 10-Day
44.78%
HV 20-Day
70.06%
HV 30-Day
63.31%
HV 60-Day
69.14%
HV Rank
51.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($4.40 target)
1
Strong Buy4
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026